Sirius Medical and Mammotome Announce Health Canada Approval for The Pintuition® System, Expanding Access Across the Country
March 10, 2026
CINCINNATI, March 10, 2026 – Mammotome, a Danaher company and globally recognized leader in breast care, and Sirius Medical, a pioneer in Surgical Marker Navigation technology, announce Health Canada approval for the Pintuition® System. This innovative system, enabled by GPSDetect® software and featuring TargetLOC® technology, delivers millimeter distance and precise directional guidance, allowing surgeons to be led directly to the target.
Now available nationwide, the Pintuition® System offers intuitive, real-time navigation designed to improve workflow efficiency and provide surgeons with greater accuracy and confidence.
“Our collaboration with Sirius Medical continues to deliver meaningful innovation to the breast care community,” said Jonathan Friend, Vice President of Global Commercial for Mammotome. “Bringing the Pintuition® System to Canada reinforces our shared commitment to equipping clinicians with advanced technologies that enhance surgical precision, streamline workflows, and ultimately support better outcomes for patients.”
Breast cancer remains a significant global health challenge. The Sirius Pintuition® System uses real-time Surgical Marker Navigation to enable surgeons to navigate with accuracy and confidence, supporting efficient, precise tumor localization.
With Health Canada approval secured for the Pintuition® System, Mammotome is well-positioned to bring the system to breast care facilities across Canada, ensuring that clinicians nationwide have access to Sirius Medical’s cutting-edge surgical localization technology.
“We are excited to extend our collaboration with Mammotome into Canada and build on the strong momentum we have created in other markets,” said Bram Schermers, CEO of Sirius Medical. “By combining Mammotome’s trusted commercial footprint with Pintuition’s innovative navigation capabilities, we are helping more clinicians adopt a localization solution that is simple, precise and reliable.”
This Health Canada approval marks a significant expansion of the companies’ exclusive distribution agreement to now include Canada and reinforces their shared commitment to advancing breast cancer care. This expanded partnership builds on the successful collaboration launched last year in the United States, Germany, Italy, and Poland.
The Pintuition® System complements Mammotome’s other industry-leading technologies available in Canada, including the Neoprobe® Gamma Detection System and the HydroMARK™ Plus Breast Biopsy Site Marker. Together, these solutions offer a robust suite of tools designed to meet the unique needs of breast surgeons and their patients.
For more information about the Pintuition® System, please click here.
About Mammotome
At Mammotome, a Danaher company, our expertise and compassion for breast care makes us the indispensable partner to physicians, clinicians and patients. Our drive for innovation is rivaled only by our compassion for the people we serve, from the clinicians and surgeons who demand consistently precise solutions, to the patients and families seeking peace of mind. Headquartered in Cincinnati, OH, Mammotome is proud to be a part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health. The Mammotome brand of products is sold in over 65 different countries throughout the world.
About Sirius Medical
With its roots deeply embedded in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivering unsurpassed yet affordable solutions that enable precise and efficient removal of tumors. The Pintuition® technology is simple, precise, affordable, CE-marked, and FDA-cleared. Sirius Medical is rapidly expanding with over 70,000 procedures worldwide in more than 250 centers and a global commercial network covering the United States, Europe and Asia Pacific.
About Danaher
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.
Media Contact:
Erica Bednar
Marketing Communications Director
Mammotome
+1 513-391-4737
Mammotomemarketing@Mammotome.com
Benjamin Tchang
Marketing Director
Sirius Medical
+31 647 852 805
Benjamin.tchang@sirius-medical.com